Daratumumab is safe and induces a rapid hematological response in light-chain amyloidosis with severe cardiac impairment
Romain Gounot, Fabien Le Bras, Jehan Dupuis, Silvia Oghina, Diane Bodez, Louise Roulin, Alizée Maarek, Amandine Ladaique, Asma Beldi‐Ferchiou, Elsa Poullot, Valérie Molinier‐Frenkel, Corinne Haïoun, Thibaud Damy, Karim Belhadj, François Lemonnier
Abstract
Systemic light-chain (AL) amyloidosis is a plasma cell disorder characterized by extracellular deposition of monoclonal immunoglobulin light chains leading to organ dysfunction. Cardiac involvement...
Topics & Concepts
Immunoglobulin light chainAL amyloidosisDaratumumabAmyloidosisMedicinePlasma cellMonoclonalExtracellularMultiple myelomaCardiac dysfunctionAntibodyPathologyMonoclonal antibodyImmunologyInternal medicineChemistryHeart failureBiochemistryAmyloidosis: Diagnosis, Treatment, OutcomesMyeloproliferative Neoplasms: Diagnosis and TreatmentChronic Myeloid Leukemia Treatments